In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a price target of $60.00. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback